Actively Recruiting
Trastuzumab Emtansine(T-DM1) After Trastuzumab Deruxtecan(T-DXd) in HER2-Positive Breast Cancer in Korea
Led by Seoul National University Hospital · Updated on 2026-04-23
100
Participants Needed
1
Research Sites
239 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Prospective observational study of trastuzumab emtansine immediately after trastuzumab deruxtecan in patients with advanced HER2-positive breast cancer in Korea
CONDITIONS
Official Title
Trastuzumab Emtansine(T-DM1) After Trastuzumab Deruxtecan(T-DXd) in HER2-Positive Breast Cancer in Korea
Who Can Participate
Eligibility Criteria
You may qualify if you...
- HER2-positive advanced (unresectable locally advanced or metastatic) breast cancer
- Prior treatment with trastuzumab deruxtecan (T-DXd) in the advanced setting
- Intention to treat with trastuzumab emtansine (T-DM1) as first therapy after progression on T-DXd
You will not qualify if you...
- Any systemic treatment other than trastuzumab emtansine (T-DM1) for breast cancer after trastuzumab deruxtecan, except endocrine agents not combined with cytotoxics or antibody-drug conjugates
- Previous treatment with trastuzumab emtansine (T-DM1) for advanced breast cancer
- Previous treatment with four or more lines of therapy for advanced breast cancer, with a cap on patients treated beyond second-line T-DXd
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Seoul National University Hospital
Seoul, South Korea, 03080
Actively Recruiting
Research Team
K
Kyung-Hun Lee, MD, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here